New study aims to pinpoint fastest Crohn's symptom relief
NCT ID NCT06249555
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This study follows 300 adults with Crohn's disease who are starting standard treatments like vedolizumab or IL-23 blockers. Researchers will track how quickly patients feel improvements in pain, fatigue, and daily functioning using simple questionnaires. The goal is to better understand when these therapies start working, helping guide future treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vedolizumab, ustekinumab, risankizumab, guselkumab, mirikizumab
- What this could lead to
- If successful, this study could help doctors predict which Crohn's treatment works fastest for each patient, improving personalized care.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ABP Research Services Corp.
Oakville, Ontario, L6L5L7, Canada
-
Alimentiv
London, Ontario, N6Z5B6, Canada
-
Brigham and Women's Hospital
Chestnut Hill, Massachusetts, 02467, United States
-
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
GI Alliance - Bellevue - Washington Gastroenterology
Bellevue, Washington, 98004, United States
-
GI Alliance - Sun City
Sun City, Arizona, 85351, United States
-
GI Alliance Research Fort Worth
Fort Worth, Texas, 76104, United States
-
GI Alliance Research Mansfield
Mansfield, Texas, 76063, United States
-
GNRR Digestive Clinics and Research Center
Brampton, Ontario, L6S0E2, Canada
-
London Health Sciences Centre
London, Ontario, N6A5A5, Canada
-
McMaster University Medical Center
Hamilton, Ontatrio, L8N 3Z5, Canada
-
Montreal General Hospital
Montreal, Quebec, H3G1A4, Canada
-
Northwestern University
Evanston, Illinois, 60611, United States
-
OR Clinic - East - GI
Portland, Oregon, 97220, United States
-
Rajbir Rai Medicine Professional Corporation
Oakville, Ontario, L6L4P7, Canada
-
Scarborough Center for Inflammatory Bowel Disease
Scarborough Village, Ontario, M1B3V4, Canada
-
The Ottawa Hospital
Ottawa, Ontario, K1H8L6, Canada
-
Toronto Immune & Digestive Health Institute Inc.
Toronto, Ontario, M6A3B4, Canada
-
University Medical Center New Orleans
New Orleans, Louisiana, 70112, United States
-
University of Alberta
Edmonton, Alberta, T6G2X8, Canada
-
University of British Columbia
Vancouver, British Columbia, V6Z2K5, Canada
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
University of North Carolina
Chapel Hill, North Carolina, 27599, United States
-
West GTA Research Inc.
Mississauga, Ontario, L5M7N4, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI reads scans to forecast Crohn's complications
- Can stem cell vesicles heal Crohn's fistulas?
- Can a new drug calm the Gut's overactive immune response in Crohn's?
- Can a new drug keep Crohn's disease in check?
- Can a biologic drug tame Crohn's without steroids? a large Real-World study investigates
- Can a glass of pomegranate juice tame gut inflammation?